论文部分内容阅读
目的 :研究系统性红斑狼疮 (SLE)患者外周血淋血细胞CD1c的表达情况及与疾病活动性之间的关系。方法 :用流式细胞仪检测了 4 7例SLE患者外周血淋巴细胞CD1c的表达及淋巴细胞表型分析 ,并评价与疾病活动性的关系。结果 :SLE活动组病人CD1c+ 细胞百分率显著增高 (P <0 0 5 ) ,CD4 + 细胞百分率显著降低 (P <0 0 1) ,CD3+ 、CD8+ 细胞百分率正常 ,CD2 0 + 细胞数增高 (P <0 0 1)。稳定期病人CD1c+ 细胞百分率正常 ,CD4 + 、CD8+ 、CD2 0 + 细胞百分率均正常。SLE患者CD1c细胞阳性率与患者SLEDAI的评分有显著的相关性 (r=0 6 8,P <0 0 1) ,与抗dsDNA抗体的表达有显著相关性 (r =0 36 ,P <0 0 5 ) ,与抗心磷脂抗体的表达有显著的相关性 (r=0 6 4 ,P <0 0 1) ,与血清C3水平有显著相关性 (r =- 0 35 ,P <0 0 5 )。活动期病人经治疗后CD1c的表达明显下降。结论 :系统性红斑狼疮患者外周血CD1c表达与疾病的活动性明显相关 ,CD1c可能在SLE脂类抗原及核酸类抗原的递呈及抗双链DNA抗体、抗磷脂抗体的产生中起重要作用。
Objective: To investigate the expression of CD1c in peripheral blood leukocytes in patients with systemic lupus erythematosus (SLE) and its relationship with disease activity. Methods: The expression of CD1c on peripheral blood lymphocytes and the phenotype of lymphocytes in 47 SLE patients were detected by flow cytometry. The relationship between the expression of CD1c and the activity of disease was evaluated. Results: The percentage of CD1c + cells was significantly increased in SLE patients (P <0.05), the percentage of CD4 + cells was significantly decreased (P <0.01), the percentage of CD3 + and CD8 + cells was normal and the number of CD20 + cells was increased 0 1). Stable patients with normal percentage of CD1c + cells, CD4 +, CD8 +, CD20 + cell percentage were normal. The positive rate of CD1c in patients with SLE was significantly correlated with the score of SLEDAI (r = 0.68, P <0.01), and was significantly correlated with the expression of anti-dsDNA antibody (r = 0 36, P 0 5) was significantly correlated with the level of serum C3 (r = -0.35, P <0.05), but not with the level of serum anticardiolipin antibody (r = . The activity of CD1c in patients after treatment decreased significantly. Conclusion: The expression of CD1c in peripheral blood of patients with systemic lupus erythematosus is significantly correlated with disease activity. CD1c may play an important role in the presentation of SLE lipids and nucleic acid antigens and the production of anti-dsDNA and antiphospholipid antibodies.